These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39402448)

  • 1. Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus.
    Spencer RH; Noonan PK; Marbury T; Menzaghi F
    BMC Nephrol; 2024 Oct; 25(1):351. PubMed ID: 39402448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus.
    Yosipovitch G; Awad A; Spencer RH; Munera C; Menzaghi F
    J Am Acad Dermatol; 2023 Aug; 89(2):261-268. PubMed ID: 37059302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
    Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F;
    N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
    Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F;
    JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis.
    Stark JG; Noonan PK; Spencer RH; Bhaduri S; O'Connor SJ; Menzaghi F
    Clin Pharmacokinet; 2023 Sep; 62(9):1231-1241. PubMed ID: 37369955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difelikefalin: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1937-1944. PubMed ID: 34674115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2.
    Fishbane S; Clegg DJ; Lerma EV; Rastogi A; Budden J; Morin I; Wen W; Menzaghi F; Topf J
    Am J Nephrol; 2024; 55(3):329-333. PubMed ID: 38253036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Difelikefalin: A New κ-Opioid Receptor Agonist for the Treatment of Hemodialysis-Dependent Chronic Kidney Disease-Associated Pruritus.
    Fugal J; Serpa SM
    Ann Pharmacother; 2023 Apr; 57(4):480-488. PubMed ID: 35942600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease.
    Lipman ZM; Yosipovitch G
    Expert Opin Pharmacother; 2021 Apr; 22(5):549-555. PubMed ID: 33190563
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.
    O'Donnell J; Preston RA; Mamikonyan G; Stone E; Isaacs R
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difelikefalin for Hemodialysis Patients with Pruritus in Japan.
    Narita I; Tsubakihara Y; Takahashi N; Ebata T; Uchiyama T; Marumo M; Okamura S; Gejyo F;
    NEJM Evid; 2023 Nov; 2(11):EVIDoa2300094. PubMed ID: 38320524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double-blind, placebo-controlled trial.
    Viscusi ER; Torjman MC; Munera CL; Stauffer JW; Setnik BS; Bagal SN
    Clin Transl Sci; 2021 Sep; 14(5):1886-1893. PubMed ID: 33982405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous difelikefalin for the treatment of hemodialysis pruritus.
    Mahmoud RH; Mahmoud O; Yosipovitch G
    Expert Rev Clin Immunol; 2024; 20(1):31-37. PubMed ID: 37847514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.
    Weiner DE; Schaufler T; McCafferty K; Kalantar-Zadeh K; Germain M; Ruessmann D; Morin I; Menzaghi F; Wen W; Ständer S
    Nephrol Dial Transplant; 2024 Jun; 39(7):1125-1137. PubMed ID: 37968132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the physical dependence potential of difelikefalin: Randomized placebo-controlled study in patients receiving hemodialysis.
    Spencer RH; Munera C; Shram MJ; Menzaghi F
    Clin Transl Sci; 2023 Sep; 16(9):1559-1568. PubMed ID: 37128642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis.
    Rastogi A; Fishbane S; Lerma E
    Expert Rev Clin Pharmacol; 2023 May; 16(5):387-400. PubMed ID: 37010031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Difelikefalin for pruritus associated with renal disease.
    Manenti L; Fenaroli P
    Drugs Today (Barc); 2022 Sep; 58(9):427-435. PubMed ID: 36102903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies.
    Topf J; Wooldridge T; McCafferty K; Schömig M; Csiky B; Zwiech R; Wen W; Bhaduri S; Munera C; Lin R; Jebara A; Cirulli J; Menzaghi F
    Kidney Med; 2022 Aug; 4(8):100512. PubMed ID: 36016762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
    Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
    Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of difelikefalin in the treatment of hemodialysis patients with pruritus: A meta-analysis and systematic review.
    Xue G; Yuan H; Fan D; Yang Y; Ma C; Liu J; Liao R
    Clin Nephrol; 2024 Apr; 101(4):155-163. PubMed ID: 38294219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.